Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Shanahan

Showing results (21-30 of 365) with videos related to

Pageof 37
Sort By:
Inflammatory Bowel Diseases|June 1, 2000
Anti-TNF therapy for Crohn's disease: a perspective (infliximab is not the drug we have been waiting for)F Shanahan
Irish Journal of Medical Science|December 1, 1994
Current concepts of the pathogenesis of inflammatory bowel diseaseF Shanahan
Lancet (London, England)|August 14, 1993
Pathogenesis of ulcerative colitisF Shanahan
Gut|April 1, 1997
Antibody 'markers' in Crohn's disease: opportunity or overstatement?F Shanahan
Alimentary Pharmacology & Therapeutics|August 15, 2017
Editorial: probiotics in inflammatory bowel disease-wrong organisms, wrong disease, or flawed concepts?F Shanahan
Gastroenterology|November 1, 1996
Closing in on the genetics of Crohn's diseaseF Shanahan
Gastroenterology|June 1, 1997
Designer drugs for inflammatory bowel diseaseF Shanahan
Gastroenterology|June 1, 1994
A mechanism for esophageal tumor-derived immunosuppressionF Shanahan
Inflammatory Bowel Diseases|June 1, 2000
Probiotics and inflammatory bowel disease: is there a scientific rationale?F Shanahan
Advances in Experimental Medicine and Biology|February 5, 2000
Intestinal lymphoepithelial communicationF Shanahan
Pageof 37

Showing results (21-30 of 365) with videos related to

Sort By:
Pageof 37
Inflammatory Bowel Diseases|June 1, 2000
Anti-TNF therapy for Crohn's disease: a perspective (infliximab is not the drug we have been waiting for)F Shanahan
Irish Journal of Medical Science|December 1, 1994
Current concepts of the pathogenesis of inflammatory bowel diseaseF Shanahan
Lancet (London, England)|August 14, 1993
Pathogenesis of ulcerative colitisF Shanahan
Gut|April 1, 1997
Antibody 'markers' in Crohn's disease: opportunity or overstatement?F Shanahan
Alimentary Pharmacology & Therapeutics|August 15, 2017
Editorial: probiotics in inflammatory bowel disease-wrong organisms, wrong disease, or flawed concepts?F Shanahan
Gastroenterology|November 1, 1996
Closing in on the genetics of Crohn's diseaseF Shanahan
Gastroenterology|June 1, 1997
Designer drugs for inflammatory bowel diseaseF Shanahan
Gastroenterology|June 1, 1994
A mechanism for esophageal tumor-derived immunosuppressionF Shanahan
Inflammatory Bowel Diseases|June 1, 2000
Probiotics and inflammatory bowel disease: is there a scientific rationale?F Shanahan
Advances in Experimental Medicine and Biology|February 5, 2000
Intestinal lymphoepithelial communicationF Shanahan
Pageof 37